Prolor Biotech Inc. (Prolor) is a development-stage biopharmaceutical company. The Company develops longer-acting versions of therapeutic proteins. Prolor is using the carboxyl terminal peptide technology. The Company’s product development program is focused on extending the life span of Human Growth Hormone, Factor IX, Anti-Obesity Peptide Oxyntomodulin, Factor VIIa, Interferon B and Erythropoietin and Atherosclerosis and rheumatoid arthritis long-acting therapies. Human Growth Hormone is used for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone. In March 2012, the Company initiated a Phase II trial of hGH-CTP in children with growth hormone deficiency. Factor IX Factor IX is offered to Hemophilia B patients. In February 2012, the Company completed the study hemophilia drug Factor VIIa in hemophilic mice and was designed to measure the potential in survival rates and in vivo recovery of Factor VIIa-CTP.